Cirtuvivint

N/A

Report date: 2026/04/07 20:00:20
NME

Base Information

Drug NameCirtuvivint
Drug Alias NameSM-08502NSC-835563
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionWnt signalling pathway inhibitorsClk dual-specificity kinase inhibitorsDYRK kinase inhibitors
TargetsDual specificity protein kinase CLKDYRK kinase
Therapy Area/IndicationsSolid tumoursMyelodysplastic SyndromesProstatic Neoplasms, Castration-Resistant +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaSpain
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesBiosplice Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesAsociación Europea y Latinoamericana SELNET para la Investigación en SarcomasEpic Sciences IncWashington University School Of Medicine +[6] 
Inactive CompaniesN/A
Active IndicationsMyelodysplastic SyndromesFallopian Tube NeoplasmsSmall Cell Lung Carcinoma +[6] 
Inactive IndicationsSolid tumoursProstatic Neoplasms, Castration-ResistantCarcinoma, Non-Small-Cell Lung +[4] 

Other Information

ATC CodeN/A
Related LinksDrugBank